UniQure Gene Therapy Failed Huntington's Trial Primary Endpoint
The experimental treatment missed its target for slowing disease progression, causing shares to drop by over half.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you generally trust pharmaceutical companies to successfully develop effective treatments for rare diseases?
UniQure's gene therapy, AMT-130, failed to meet its primary endpoint in a 12-patient study for Huntington's disease. Following the announcement, the company's shares fell 55% in premarket trading.
Why it matters
Huntington's disease remains an incurable brain disorder causing significant cognitive and behavioral decline. The absence of approved therapies that can effectively slow its progression makes any failure in clinical development a significant setback for the field.
The study tracked 12 high-dose patients over 48 months, showing a 44% slowing of disease progression compared to an external control. Despite this result, the trial failed to hit its primary statistical endpoint.
The players
UniQure
A biotechnology company focused on developing gene therapies for severe genetic disorders, including Huntington's disease.
The details
The experimental drug AMT-130 is a gene therapy—a treatment that alters the genetic material within a patient's cells—designed to address the underlying cause of Huntington's disease. The study evaluated its efficacy by measuring the rate of decline in motor, behavioral, and cognitive function against a group of patients not receiving the intervention. Researchers utilized a four-year analysis period to determine if the genetic modification successfully mitigated the neurodegenerative effects of the disorder.
Timeline
September 29, 2026: UniQure reported the trial failure and shares plummeted.
48 months: Duration of the analysis window for disease progression.
The Tech Race
Developing treatments for Huntington's disease remains one of the most difficult challenges in neurodegenerative medicine. This result highlights the significant gap in the field, as no drug has yet reached the market with the capability to slow the progression of this inherited brain disorder.
There are currently no approved drugs that slow the progression of Huntington's disease for patients or their families. Because this trial failed to meet its primary endpoint, the therapy remains strictly an experimental research candidate rather than a treatment option.
The takeaway
This failure underscores the high barrier to success in gene-based interventions for complex neurodegenerative disorders. Observers should track future updates from UniQure to see if subsequent analyses or different patient cohorts yield any viable regulatory path forward.
Further reading
For broader context on current clinical advancements, visit our Biotech section.
Live Poll
Do you generally trust pharmaceutical companies to successfully develop effective treatments for rare diseases?
